Evidence map›Paper›PMID 27404095›Full record

ArticlePloS one2016

Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation.

Martin W von Websky, Koji Kitamura, Isis Ludwig-Portugall, Christian Kurts, Maximilian von Laffert, Joel LeMaoult, Edgardo D Carosella, Kareem Abu-Elmagd, Joerg C Kalff, Nico Schäfer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Adipose-derived mesenchymal stem cells suppress of acute rejection in small bowel transplantation.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Martin W von WebskyDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Koji KitamuraDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Isis Ludwig-PortugallInstitute for Experimental Immunology, University of Bonn, Germany.
Christian KurtsInstitute for Experimental Immunology, University of Bonn, Germany.
Maximilian von LaffertCharité Berlin, Institute of Pathology, Berlin, Germany.
Joel LeMaoultCEA, iMETI, Research Division in Hematology and Immunology, Saint-Louis Hospital, Paris, France.
Edgardo D CarosellaCEA, iMETI, Research Division in Hematology and Immunology, Saint-Louis Hospital, Paris, France.
Kareem Abu-ElmagdTransplant Center, Cleveland Clinic, Cleveland, Ohio, United States of America.
Joerg C KalffDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Nico SchäferDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
University Hospital Bonn · DECommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversity of Bonn · DECharité - Universitätsmedizin Berlin · DECleveland Clinic · USKyoto University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8+ T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4+ populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4+/CD25+/FoxP3+Treg-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8+ T-cell populations either directly or by induction of non-classical Treg populations.

Indexed as

AnimalsGraft RejectionHLA-G AntigensImmunologic FactorsIntestinesMaleRatsRecombinant ProteinsTransplantation, HomologousHLA-G AntigensImmunologic FactorsRecombinant Proteins

Identifiers

PMID27404095
PMCPMC4942037
OpenAlexW2471873247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.